Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer
Disease control
Recruiting now
This early-stage trial tests a new drug called 177Lu-PSMA-VG01 in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has spread and stopped responding to hormone therapy. The drug is designed to deliver radiation directly to cancer cells, aiming to sh…
Phase: PHASE1 • Sponsor: VitsGen Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC